Galapagos NV (Galapagos NV) ROE % Adjusted to Book Value : 26.72% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV ROE % Adjusted to Book Value?

Galapagos NV's ROE % for the quarter that ended in Dec. 2023 was 23.51%. Galapagos NV's PB Ratio for the quarter that ended in Dec. 2023 was 0.88. Galapagos NV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 26.72%.

Galapagos NV ROE % Adjusted to Book Value Historical Data

The historical data trend for Galapagos NV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV ROE % Adjusted to Book Value Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

1.74

-5.79

-3.09

-7.49

9.17

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-30.17	3.95	0.83	4.86	26.72

Competitive Comparison of Galapagos NV's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Galapagos NV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Galapagos NV's ROE % Adjusted to Book Value falls into.

Galapagos NV ROE % Adjusted to Book Value Calculation

Galapagos NV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.07%	/	0.88
	=	9.17%

Galapagos NV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	23.51%	/	0.88
	=	26.72%

Galapagos NV ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Galapagos NV's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.